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Aging alters brain structure and function. Personal health markers and modifiable lifestyle
factors are related to individual brain aging as well as to the risk of developing Alzheimer’s
disease (AD). This study used a novel magnetic resonance imaging (MRI)-based biomarker
to assess the effects of 17 health markers on individual brain aging in cognitively
unimpaired elderly subjects. By employing kernel regression methods, the expression of
normal brain-aging patterns forms the basis to estimate the brain age of a given new
subject. If the estimated age is higher than the chronological age, a positive brain age
gap estimation (BrainAGE) score indicates accelerated atrophy and is considered a risk
factor for developing AD. Within this cross-sectional, multi-center study 228 cognitively
unimpaired elderly subjects (118 males) completed an MRI at 1.5Tesla, physiological and
blood parameter assessments. The multivariate regression model combining all measured
parameters was capable of explaining 39% of BrainAGE variance in males (p < 0.001)
and 32% in females (p < 0.01). Furthermore, markers of the metabolic syndrome as well
as markers of liver and kidney functions were profoundly related to BrainAGE scores in
males (p < 0.05). In females, markers of liver and kidney functions as well as supply of
vitamin B12 were significantly related to BrainAGE (p < 0.05). In conclusion, in cognitively
unimpaired elderly subjects several clinical markers of poor health were associated with
subtle structural changes in the brain that reflect accelerated aging, whereas protective
effects on brain aging were observed for markers of good health. Additionally, the relations
between individual brain aging and miscellaneous health markers show gender-specific
patterns. The BrainAGE approach may thus serve as a clinically relevant biomarker for the
detection of subtly abnormal patterns of brain aging probably preceding cognitive decline
and development of AD.
Keywords: aging, Alzheimer’s disease (AD), BrainAGE , lifestyle, magnetic resonance imaging (MRI), voxel-based
morphometry (VBM)
INTRODUCTION
The global prevalence of dementia is projected to rise sharply
over the next decades. By 2050, 1 in 85 persons worldwide will
be affected by Alzheimer’s disease (AD), the most common form
of dementia (Brookmeyer et al., 2007). Manifold pathological
changes accumulate over many years or decades before cogni-
tive decline occurs gradually, with dementia representing the final
stage of the pathological cascade (Frisoni et al., 2010; Jack et al.,
2010). These pathological changes include precocious and/or
accelerated brain aging (Fotenos et al., 2008; Driscoll et al., 2009;
Sluimer et al., 2009; Wang et al., 2009; Spulber et al., 2010; Clark
et al., 2012). Recently, atrophic regions detected in AD patients
were found to largely overlap with those regions showing a nor-
mal age-related decline in healthy control subjects (Dukart et al.,
2011). Hence, early identification of neuroanatomical changes
deviating from the normal age-related atrophy pattern has the
potential to improve clinical outcomes in the disease course
through early treatment or prophylaxis (Ashburner et al., 2003).
Though “healthy” brain aging has been found to follow highly
coordinated and sequenced patterns of brain tissue loss and cere-
brospinal fluid (CSF) expansion (Pfefferbaum et al., 1994; Good
et al., 2001; Resnick et al., 2003; Raz and Rodrigue, 2006; Terribilli
et al., 2011), multiple factors affect and modify those individual
trajectories. Several markers of poor health and/or inappropriate
lifestyle (including obesity, high cholesterol, nicotine and alco-
hol abuse, hypertension, diabetes, as well as elevated serum total
homocysteine (tHcy) and lower levels of vitamin B12) have been
related to the risk of accelerated brain atrophy, cognitive decline,
and even dementia (Clarke et al., 1998, 2007; Ellinson et al., 2004;
Clarke, 2006; Steele et al., 2007; Solfrizzi et al., 2008; Chen et al.,
2009; Fitzpatrick et al., 2009; Debette et al., 2010; Oulhaj et al.,
2010; Zylberstein et al., 2011). Furthermore, the combination of
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risk factors was found to further boost the risk (Luchsinger et al.,
2005). Particularly, components of the metabolic syndrome, i.e.,
a higher body mass index (BMI), elevated cholesterol and fasting
glucose levels, and a higher diastolic blood pressure (DBP), are
associated with a greater rate of brain atrophy (Enzinger et al.,
2005) as well as an increased risk of dementia (Middleton and
Yaffe, 2009).
In contrast, a healthy and well-balanced lifestyle (includ-
ing physical activity, normal body weight, smoking cessation,
Mediterranean diet, and moderate alcohol intake) was shown to
lower the risk of cognitive decline and dementia (Peters et al.,
2008; Solfrizzi et al., 2008; Luchsinger and Gustafson, 2009;
Scarmeas et al., 2009; Xu et al., 2009; Erickson et al., 2010; Feart
et al., 2010; Frisardi et al., 2010; Gu et al., 2010; Nepal et al.,
2010). Maintaining cardiovascular health in midlife was recently
suggested to be the most promising strategy for preventing cog-
nitive impairment and dementia in late life (Hughes and Ganguli,
2009).
Based on the widespread but well-ordered brain tissue loss
that occurs with healthy aging into senescence (Good et al.,
2001), we previously proposed a modeling approach to iden-
tify abnormal aging-related brain atrophy that may precede the
onset of cognitive decline and clinical symptoms. We introduced
a novel BrainAGE approach (Franke et al., 2010, 2012b) based
on a database of single time-point structural magnetic resonance
imaging (MRI) data that aggregates the complex, multidimen-
sional aging patterns across the whole brain to one single value,
i.e., the estimated brain age. The difference between estimated
and true chronological age will reveal the individual brain age gap
estimation (BrainAGE) score. Consequently, the BrainAGE score
directly quantifies subtle deviations in “normal” age-related brain
atrophy by analyzing only one standard MRI per subject, with
positive BrainAGE scores indicating accelerated structural brain
aging and negative BrainAGE scores indicating decelerated struc-
tural brain aging. Recent work has demonstrated that increased
BrainAGE scores in subjects with mild cognitive impairment
(MCI) related to an increased risk of converting to AD, with each
additional year in the baseline BrainAGE score being associated
with a 10% greater risk of converting to AD within the next three
years (Gaser et al., 2013). Furthermore, we observed profound
relationships between BrainAGE, disease severity, prospective
worsening of cognitive functions (Franke et al., 2012a), conver-
sion to AD (Gaser et al., 2013), as well as diabetes mellitus type 2
(Franke et al., 2013).
In this study, we implemented the BrainAGE method to
explore and quantify the effects of several physiological and clini-
cal chemistry markers of personal health on individual BrainAGE
scores in a subsample of cognitively unimpaired older adults
from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
database. Since men and women were found to differ in basic
aspects of their normal function, their experience of the same
illness (Pinn, 2003), probable risk factors on individual brain
aging were separately examined in men and women. We expect
gender-specific patterns in the relations between BrainAGE scores
and health markers. Additionally, we expect the combination of
the most significant risk factors to be associated with an even
greater effect on individual BrainAGE scores than each factor
independently.
METHODS
SUBJECTS
To train the age estimation framework, we used T1-weighted
MRI data of 561 healthy subjects (250 male) from the publicly
accessible IXI cohort (http://www.brain-development.org; data
downloaded in September 2011) aged 20–86 years [mean (SD) =
48.6 (16.5) years], which were collected on three different scan-
ners (Philips 1.5T, General Electric 1.5T, Philips 3.0T). For more
sample details see Franke et al. (2010).
The current BrainAGE analyses were conducted using data
obtained from the ADNI database (www.loni.ucla.edu/ADNI).
ADNI utilizes the following diagnostic criteria to classify the
subjects into (1) Normal subjects (NO): “Mini-Mental State
Examination” (MMSE; Cockrell and Folstein, 1988; test range 0–
30) scores between 24 and 30 (inclusive), a “Clinical Dementia
Rating” (CDR; Morris, 1993; test range 0–3) score of 0,
non-depressed, non-MCI, and non-demented; (2) MCI sub-
jects: MMSE scores between 24 and 30 (inclusive), a mem-
ory complaint, objective memory loss measured by education
adjusted scores on Wechsler Memory Scale Logical Memory II,
a CDR score of 0.5, absence of significant levels of impair-
ment in other cognitive domains, essentially preserved activi-
ties of daily living, and an absence of dementia; (3) mild AD:
MMSE scores between 20 and 26 (inclusive), CDR scores of
0.5 or 1.0, and meeting NINCDS/ADRDA criteria for probable
AD. Detailed description of the ADNI inclusion and exclusion
criteria is available at http://www.adni-info.org/Scientists/Pdfs/
adniproceduresmanual12.pdf.
Adopting the diagnostic classification fromADNI, we included
all subjects who (i) were diagnosed as NO (i.e., cognitively unim-
paired) at their baseline visit; for whom (ii) MRI data (1.5T), and
(iii) a battery of physiological and clinical chemistry parameters
at baseline were available [i.e., albumin, alanin-aminotransferase
(ALT), aspartat-aminotransferase (AST), systolic (SBP) and dias-
tolic blood pressure (DBP), BMI, γ-glutamyltransferase (GGT),
glucose, mean erythrocyte cell volume (MCV), thyroid stim-
ulating hormone (TSH), triglycerides, total bilirubin, creati-
nine, tHcy, uric acid, cholesterol, vitamin B12; Table 1]. Exact
procedures of collection and processing of the physiological,
clinical chemistry and MRI data can be found in the “ADNI
Procedures Manual” (http://www.adni-info.org/Scientists/Pdfs/
adniproceduresmanual12.pdf).
Thus, the male test sample consisted of 118 cognitively unim-
paired men, aged 60–88 years, with a mean age of 75.8 ± 5.3
years. Mean MMSE at baseline was 29.0 ± 1.1. The female test
sample contained 110 cognitively unimpaired women, aged 62–
90 years, with a mean age of 76.1 ± 4.8 years. Mean MMSE
at baseline was 29.2 ± 0.9. More cognitive test scores for base-
line and available follow-up assessments are presented in Table 2.
Additionally, a list of subjects included in this study is provided in
Supplement 1.
PREPROCESSING OF MRI DATA AND DATA REDUCTION
As described in Franke et al. (2010), preprocessing of the T1-
weighted images was done using the SPM8 package (http://
www.fil.ion.ucl.ac.uk/spm/) and the VBM8 toolbox (http://dbm.
neuro.uni-jena.de), running under MATLAB. All T1-weighted
images were corrected for bias-field inhomogeneities, then
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Table 1 | Baseline characteristics of all measured physiological and clinical chemistry parameters in male and female test samples.
MALE FEMALE p-value (male
vs. female)
n Mean (SD) p-value (test
for
normality)
n Mean (SD) p-value (test
for
normality)
Albumin (g/dl) 115 4.20 (0.31) 0.012 107 4.16 (0.31) n.s. n.s.
ALT (U/l) 115 22.52 (8.62) 0.001 107 18.46 (5.90) 0.001 0.0001
AST (U/l) 112 24.10 (5.75) 0.001 107 23.31 (5.40) 0.001 n.s.
Direct Bilirubin (mg/dl) 112 0.16 (0.07) 0.001 107 0.12 (0.05) 0.001 0.0001
Total Bilirubin (mg/dl) 115 0.61 (0.30) 0.001 107 0.46 (0.20) 0.001 0.0001
SBP (mmHg) 118 134.9 (17.21) 0.018 110 134.1 (16.69) n.s. n.s.
DBP (mmHg) 118 75.14 (9.66) n.s. 110 74.26 (10.90) n.s. n.s.
BMI (kg/m2) 117 26.76 (3.75) n.s. 110 26.55 (4.99) 0.001 n.s.
Cholesterol (mg/dl) 116 178.0 (34.21) 0.002 108 209.8 (39.45) n.s. 0.0001
Creatinine (mg/dl) 116 1.07 (0.23) 0.001 108 0.83 (0.18) 0.001 0.0001
GGT (U/l) 116 26.11 (16.80) 0.001 108 22.53 (15.34) 0.001 0.002
Glucose (mg/dl) 115 104.2 (25.77) 0.001 107 99.9 (15.63) 0.001 n.s.
MCV (fL) 114 90.42 (4.94) 0.03 108 89.26 (5.44) n.s. n.s.
TSH (μIU/mL) 115 1.92 (1.20) 0.001 109 2.01 (1.44) 0.001 n.s.
tHcy (μmol/l) 118 10.56 (2.98) 0.001 108 9.29 (2.45) 0.002 0.001
Triglycerides (mg/dl) 116 152.3 (91.9) 0.001 108 133.9 (76.5) 0.001 0.05
Uric Acid (mg/dl) 116 6.03 (1.30) n.s. 108 5.02 (1.39) 0.04 0.0001
Vitamin B12 (ng/l) 113 477.3 (317.1) 0.001 108 600.6 (414.0) 0.001 0.002
ALT, alanin-aminotransferase; AST, aspartat-aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; GGT, γ -glutamyltransferase; MCV, mean
erythrocyte cell volume; SBP, systolic blood pressure; TSH, thyroid stimulating hormone; tHcy, total homocysteine; n.s., not significant.
Table 2 | Cognitive characteristics in male and female test samples.
MALE FEMALE
n Min–max Mean (SD) n Min–max Mean (SD)
M
M
S
E
Baseline 118 25–30 29.0 (1.0) 110 26–30 29.2 (0.9)
12 months follow-up 108 24–30 29.1 (1.3) 102 25–30 29.2 (1.1)
24 months follow-up 106 24–30 29.1 (1.2) 95 26–30 29.1 (1.1)
36 months follow-up 88 25–30 28.8 (1.3) 88 24–30 29.2 (1.1)
C
D
R
Baseline 118 0.0–0.0 0.0 (0.0) 110 0.0–0.0 0.0 (0.0)
12 months follow-up 106 0.0–0.5 0.0 (0.1) 100 0.0–0.5 0.0 (0.1)
24 months follow-up 103 0.0–0.5 0.1 (0.2) 92 0.0–0.5 0.0 (0.1)
36 months follow-up 84 0.0–1.0 0.1 (0.2) 84 0.0–1.0 0.1 (0.2)
A
D
A
S
Baseline 118 1–20 10.2 (3.9) 110 1–21 8.7 (4.3)
12 months follow-up 105 0–21 10.0 (4.7) 102 1–23 7.6 (4.2)
24 months follow-up 106 2–24 10.1 (4.9) 93 0–26 8.6 (4.9)
36 months follow-up 87 1–23 9.6 (4.8) 82 1–32 8.1 (4.7)
ADAS, Alzheimer’s Disease Assessment Scale; CDR, Clinical Dementia Rating; MMSE, Mini-Mental State Examination.
spatially normalized and segmented into gray matter (GM),
white matter (WM), and CSF within the same generative model
(Ashburner and Friston, 2005). As recently described (Gaser,
2009), the segmentation procedure was further extended by
accounting for partial volume effects (Tohka et al., 2004), apply-
ing adaptive maximum a posteriori estimations (Rajapakse et al.,
1997), and using a hidden Markov Random Field model (Cuadra
et al., 2005). After segmentation, only GM images were used.
The images were processed with affine registration and smoothed
with 8-mm full-width-at-half-maximum (FWHM) smoothing
kernels. Spatial resolution was set to 8mm. Data reduction was
performed by applying principal component analysis (PCA),
utilizing the “Matlab Toolbox for Dimensionality Reduction”
(http://ict.ewi. tudelft.nl/∼lvandermaaten/Home.html).
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AGE ESTIMATION FRAMEWORK
The BrainAGE framework utilizes a machine-learning pattern
recognition method, namely relevance vector regression (RVR;
Tipping, 2001). It was recently developed to model healthy brain
aging and subsequently estimate individual brain ages based on
T1-weighted images (Franke et al., 2010). As suggested by Franke
et al. (2010), the kernel was chosen to be a polynomial of degree
1, since age estimation accuracy was shown to not improve
when choosing non-linear kernels. Thus, parameter optimization
during the training procedure was not necessary.
In general, the age regression model is trained with chrono-
logical age and preprocessed whole brain structural MRI data (as
described in “Preprocessing ofMRI Data and Data Reduction”) of
the training sample, resulting in a complexmodel of healthy brain
aging (Figure 1A, left panel). Put in other words, the algorithm
uses those whole-brain MRI data from the training sample that
represent the prototypical examples within the specified regres-
sion task (i.e., healthy brain aging). Additionally, voxel-specific
weights are calculated that represent the importance of each voxel
within the specified regression task (i.e., healthy brain aging). For
an illustration of the most important features (i.e., the impor-
tance of voxel locations for regression with age) that were used
by the RVR to model normal brain aging and more detailed
information please refer Franke et al. (2010).
Subsequently, the brain age of a test subject can be estimated
using the individual tissue-classified MRI data (as described in
“Preprocessing of MRI Data and Data Reduction”), aggregating
the complex, multidimensional aging pattern across the whole
brain into one single value (Figure 1A, right panel). In other
words, all the voxels of the test subject’s MRI data are weighted
by applying the voxel-specific weighting matrix. Then, the brain
age is calculated by applying the regression pattern of healthy
brain aging and aggregating all voxel-wise information across
the whole brain. The difference between estimated and chrono-
logical age will reveal the individual brain age gap estimation
(BrainAGE) score, with positive values indicating accelerated
structural brain aging and negative values indicating decelerated
structural brain aging. Consequently, the BrainAGE score directly
quantifies the amount of acceleration or deceleration of brain
aging (Figure 1B). For example, if a 70 years old individual has a
BrainAGE score of+5 years, this means that this individual shows
the typical atrophy pattern of a 75 years old individual.
Recent work has demonstrated that this method provides reli-
able and stable estimates (Franke et al., 2012a). Specifically, the
BrainAGE scores calculated from two shortly delayed scans on the
same MRI scanner, as well as on separate 1.5T and 3.0T scan-
ners, produced intraclass correlation coefficients (ICC) of 0.93
and 0.90, respectively.
Within this study, the BrainAGE framework was applied
using the preprocessed GM images (as described in the section
“Preprocessing of MRI Data and Data Reduction”). For train-
ing the model as well as for predicting individual brain ages,
we used “The Spider” (http://www.kyb.mpg.de/bs/people/spider/
main.html), a freely available toolbox running under MATLAB.
STATISTICAL ANALYSIS
Descriptive statistics were used to summarize all variables.
Physiological and clinical chemistry parameters as markers for
of individual health status were compared between the male and
female sample using analysis of variance (ANOVA) for normally
distributed continuous variables or Kruskal-Wallis tests for vari-
ables that were not normally distributed. Normality was tested
using Shapiro-Wilk tests. Since the ADNI database includes data
from about 50 different study sites across the U.S. and Canada, the
BrainAGE scores were compared between the several sites using
analysis of variance (ANOVA) to test for probable site-specific
effects.
The effect of gender within the relationships between
BrainAGE and physiological and clinical chemistry parame-
ters were investigated by performing analysis of covariance
(ANCOVA). Each specific ANCOVA included all those subjects
whoweremeasured in each specific health and lifestyle parameter,
FIGURE 1 | Depiction of the BrainAGE concept. (A) The model of healthy
brain aging is trained with the chronological age and preprocessed structural
MRI data of a training sample (left; with an illustration of the most important
voxel locations that were used by the age regression model). Subsequently,
the individual brain ages of previously unseen test subjects are estimated,
based on their MRI data (blue; picture modified from Schölkopf and Smola,
2002). (B) The difference between the estimated and chronological age
results in the BrainAGE score, positive BrainAGE scores indicate accelerated
brain aging. (Image reproduced from Franke et al. (2012a), with permission
from Hogrefe Publishing, Bern).
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sub-grouped by gender. For each specific ANCOVA, the model
fitted separate lines for the male and the female sample, thus
allowing the intercept as well as the slopes to vary between both
test samples.
Gender-specific effects of individual health parameters on
BrainAGE were analyzed using linear regression models, specif-
ically partial least squares (PLS). PLS included all subjects that
were measured in all 17 physiological and clinical chemistry
parameters, resulting in n = 107 for the male sample (mean age
75.7 ± 5.3 years) and n = 104 for the female sample (mean age
76.1 ± 4.8 years). However, as not all subjects were measured in
all 17 physiological and clinical chemistry parameters, additional
correlation analyses were performed for the most significant vari-
ables contributing to the variance in BrainAGE (based on the
PLS variable weights) to further explore the relationships between
BrainAGE and each of those physiological and clinical chemistry
parameters. In order to control for covariates, Pearson’s pairwise
correlation for normally distributed variables or Spearman’s for
variables that are not normally distributed with adjustment for
age and study site was used.
To quantify gender-specific effects of extremely low vs.
extremely high levels in the most significant physiological and
clinical chemistry parameters on BrainAGE, both test samples
(i.e., male and female) were split up into quartiles for each of
these clinical parameters. To illustrate the relationships between
individual brain aging and extreme levels in each of these vari-
ables, the BrainAGE scores in the 1st quartile (lowest 25% of
values) of each physiological and clinical chemistry parameter
were tested against the BrainAGE scores in 4th quartile (high-
est 25% of values) of each physiological and clinical chemistry
parameter, using Students’ t-test for normally distributed param-
eters or Mann-Whitney test for those parameters that were
not normally distributed. To control for multiple comparisons,
Bonferroni-Holm correction (Holm, 1979) was applied, adjust-
ing the p-value for the number of variables analyzed (i.e., 4;
p < 0.05).
Additionally, to control for equal distribution in terms of
chronological age within the 1st and 4th quartile groups as well
as to explore the effects of extremely low vs. extremely high lev-
els in the most significant physiological and clinical chemistry
parameters on cognitive (i.e., Alzheimer’s Disease Assessment
Scale ADAS; Mohs and Cohen, 1988; Mohs, 1996) and disease
severity scores (i.e., MMSE, CDR), Students’ t-test for normally
distributed parameters or Mann-Whitney test for those parame-
ters that were not normally distributed were computed. Similar,
Bonferroni-Holm-adjusted p-values were used to determine sig-
nificance (p < 0.05).
Furthermore, the effect of combining the most significant
variables (based on the PLS variable weights) on BrainAGE was
explored in both test samples. Thereto, groups with “healthy”
as well as “risky” clinical markers were formed. The groups
with “healthy” clinical markers included all subjects who had
values equal to or below the medians of the most significant
physiological and clinical chemistry parameters (except for vita-
min B12, as higher values in vitamin B12 are associated with
more sufficient vitamin B12 supply and therefore “better health”).
The groups with “risky” clinical markers included all subjects
who had values equal to or above the medians of the most sig-
nificant physiological and clinical chemistry parameters (except
for vitamin B12, as lower values in vitamin B12 are associated
with an insufficient vitamin B12 supply and therefore “poorer
health”). Students’ t-test was used to test these groups with
combined “healthy” vs. combined “risky” clinical health marker
values.
The Shapiro-Wilk test as well as PLS was performed using
JMP 9.0 (www.jmp.com). All other testing was performed using
MATLAB 7.11. (www.mathworks.com).
RESULTS
GROUP CHARACTERISTICS
In the male as well as in the female test sample, the mean
BrainAGE score was 0.0 years. There were no effects for scanning
sites [male: F(44, 62) = 1.1, p = 0.35; female: F(45, 58) = 1.0, p =
0.43]. The mean values of the physiological and clinical chem-
istry data evaluated here are given in Table 1. In the male test
sample, only BMI, DBP, and uric acid were normally distributed.
In the female test sample, albumin, SBP, DBP, cholesterol, and
MCVwere normally distributed. Men showed significantly higher
parameter levels than women in ALT, Direct Bilirubin, Total
Bilirubin, Creatinine, GGT, tHcy, Triglycerides, and Uric Acid,
whereas women show significantly higher levels than men in
Cholesterol and B12 (Table 1).
Table 3 | ANCOVA results for BrainAGE scores and health and
lifestyle variables.
Model
Gender Variable value Gender × value
F p F p F p
Albumin (g/dl) 0.03 0.87 0.47 0.49 0.17 0.68
ALT (U/l) 0.16 0.69 0.58 0.45 3.90 0.05
AST (U/l) 0.01 0.91 0.04 0.84 5.86 0.02
Direct Bilirubin (mg/dl) 0.09 0.77 0.46 0.50 0.21 0.65
Total Bilirubin (mg/dl) 0.56 0.45 3.74 0.06 1.23 0.27
SBP (mmHg) 0.03 0.87 1.14 0.29 0.04 0.85
DBP (mmHg) 0.06 0.80 6.40 0.01 0.85 0.36
BMI (kg/m2) 0.05 0.82 18.81 0.0001 4.26 0.04
Cholesterol (mg/dl) 0.00 0.99 0.39 0.53 0.81 0.37
Creatinine (mg/dl) 0.71 0.40 1.47 0.23 0.01 0.93
GGT (U/l) 0.44 0.51 12.49 0.001 0.00 0.98
Glucose (mg/dl) 0.09 0.76 0.96 0.33 0.06 0.81
MCV (fL) 0.03 0.86 0.68 0.41 0.24 0.62
TSH (μIU/mL) 0.08 0.77 3.11 0.08 0.22 0.64
tHcy (μmol/l) 0.17 0.68 3.82 0.05 0.05 0.82
Triglycerides (mg/dl) 0.07 0.79 0.00 0.96 0.25 0.62
Uric Acid (mg/dl) 1.42 0.23 6.98 0.01 2.52 0.11
Vitamin B12 (ng/l) 0.23 0.63 1.7 0.19 2.47 0.12
ALT, alanin-aminotransferase; AST, aspartat-aminotransferase; BMI, body mass
index; DBP, diastolic blood pressure; GGT, γ -glutamyltransferase; MCV, mean
erythrocyte cell volume; SBP, systolic blood pressure; TSH, thyroid stimulating
hormone; tHcy, total homocysteine; bold type = significant test results.
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GENDER-SPECIFIC EFFECTS
ANCOVAs were performed in order to investigate the effects
of gender on the relationships between BrainAGE scores and
all physiological and clinical chemistry data (Table 3). Within
the whole test sample, BrainAGE scores varied with BMI (p <
0.0001), DBP (p < 0.01), GGT (p < 0.001), and uric acid (p <
0.01). Interactions with gender were found for ALT (p < 0.05),
AST (p < 0.05), and BMI (p < 0.05). Thus, the effects of
health parameters on BrainAGE show gender-specific patterns.
Consequently, the following analyses were performed on males
and females separately.
MALE SAMPLE
For men, when combining all measured physiological and clin-
ical chemistry parameters in the PLS regression model, 39% of
variance within the BrainAGE score was attributed to the phys-
iological and clinical chemistry parameters under consideration
(R2 = 0.39, p < 0.001). BMI, uric acid, GGT, and DBP con-
tributed most to the variance in BrainAGE (Figure 2). More
specifically, higher BrainAGE scores were significantly correlated
to higher BMI (r = 0.35, p < 0.001), increased DBP (r = 0.19,
p < 0.05), increased levels of GGT (r = 0.20, p < 0.05), and
FIGURE 2 | PLS regression model of the male sample. When modeling
the relationships between BrainAGE and health parameters, the PLS
regression model explained 39% of variance in BrainAGE (p < 0.001): BMI,
uric acid, GGT, and DBP are the most significant physiological and clinical
chemistry parameters as they added most to the explained variance in
BrainAGE (top chart) and also showed the highest variable weights, i.e., the
highest impact in the regression model (bottom chart).
increased levels of uric acid (r = 0.25, p < 0.01). This indicates
a strong link between accelerated brain aging and elevated levels
of these four parameters.
To quantify the effects of these most significant physiological
and clinical chemistry parameters on BrainAGE, the BrainAGE
scores of subjects with extremely low levels (i.e., 1st quartile
group) were tested against the BrainAGE scores of subjects with
extremely high levels (i.e., 4th quartile group) in each of those
four parameters (Figure 3). In all four parameters higher values
were related to higher BrainAGE scores, thus suggesting acceler-
ated brain aging. The absolute difference of the mean BrainAGE
scores in the lowest vs. the highest quartile group was 7.5 years for
BMI (p < 0.001), 6.6 years for DBP (p < 0.01), 7.5 years for GGT
(p < 0.01), and 5.6 years for uric acid (p < 0.05). All analyses
survived the Bonferroni-Holm correction. Neither chronologi-
cal age, nor cognitive scores at baseline and follow-up differed
between 1st vs. 4th quartile groups (Table 4).
Combining these four parameters, the effects on BrainAGE
scores were compounded. More precisely, male subjects with val-
ues equal to or below the medians of BMI, DBP, GGT, and
uric acid (“healthy” clinical markers; n = 9) vs. male subjects
with values equal to or above the medians of BMI, DBP, GGT,
and uric acid (“risky” clinical markers; n = 14) showed mean
BrainAGE scores of −8.01 vs. 6.69 years, respectively (p = 0.015;
Figure 4). However, neither chronological age, nor cognitive
scores at baseline and follow-up differed between both groups
(Table 5).
Taken together, the results indicate a strong link between phys-
iological and clinical health markers and structural brain aging in
men, whereas no effects on cognitive scores could be found.
FIGURE 3 | The effects of extremely low vs. extremely high levels in
clinical markers on BrainAGE in the male sample. Mean BrainAGE
scores of male subjects in the 1st (plain) and the 4th quartiles (filled
squares) of the most significant physiological and clinical chemistry
parameters (i.e., BMI, uric acid, GGT, and DBP). Error bars depict the
standard error of the mean (SEM). [∗p < 0.05 after Bonferroni-Holm
correction].
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Table 4 | Means (SD) of BrainAGE scores, chronological age and cognitive scores in the 1st and 4th quartile groups of the four most significant
physiological and clinical chemistry parameters within the male sample.
MALE BMI DBP GGT Uric acid
1st
quartile
4th
quartile
p 1st
quartile
4th
quartile
p 1st
quartile
4th
quartile
p 1st
quartile
4th
quartile
p
BrainAGE score
(years)
−2.84
(6.96)
4.7
(7.29)
<0.05
−3.26
(7.03)
3.35
(7.59)
<0.05
−2.34
(9.08)
5.17
(6.83)
<0.05
−4.10
(8.03)
1.51
(8.79)
<0.05
Chronological age
(years)
77.0
(6.4)
75.5
(4.1)
n.s.
78.4
(5.7)
75.3
(5.1)
n.s.
76.7
(4.8)
74.2
(4.5)
n.s.
76.4
(5.2)
74.3
(5.5)
n.s.
MMSE score
(baseline)
29.1
(0.9)
29.0
(0.9)
n.s.
29.3
(0.9)
29.0
(1.0)
n.s.
28.7
(1.3)
29.1
(1.2)
n.s.
28.8
(1.1)
28.8
(1.1)
n.s.
MMSE score
(12 months follow-up)
29.3
(1.0)
29.0
(1.6)
n.s.
29.3
(1.0)
28.9
(1.5)
n.s.
29.0
(1.3)
29.2
(1.1)
n.s.
29.2
(1.0)
28.8
(1.5)
n.s.
MMSE score
(24 months follow-up)
29.1
(0.9)
28.8
(1.5)
n.s.
29.0
(1.1)
29.3
(1.0)
n.s.
29.2
(0.9)
28.9
(1.5)
n.s.
29.6
(0.7)
28.5
(1.6)
n.s.
MMSE score
(36 months follow-up)
29.0
(1.2)
28.6
(1.4)
n.s.
29.1
(1.3)
28.8
(1.5)
n.s.
29.0
(1.2)
28.7
(1.5)
n.s.
29.3
(1.4)
28.9
(1.2)
n.s.
CDR score
(baseline)
0.00
(0.00)
0.00
(0.00)
n.s.
0.00
(0.00)
0.00
(0.00)
n.s.
0.00
(0.00)
0.00
(0.00)
n.s.
0.00
(0.00)
0.00
(0.00)
n.s.
CDR score
(12 months follow-up)
0.00
(0.00)
0.09
(0.20)
n.s.
0.05
(0.15)
0.04
(0.14)
n.s.
0.06
(0.17)
0.02
(0.11)
n.s.
0.03
(0.11)
0.04
(0.14)
n.s.
CDR score
(24 months follow-up)
0.02
(0.10)
0.10
(0.20)
n.s.
0.05
(0.15)
0.07
(0.17)
n.s.
0.04
(0.14)
0.07
(0.18)
n.s.
0.10
(0.21)
0.06
(0.17)
n.s.
CDR score
(36 months follow-up)
0.07
(0.18)
0.15
(0.28)
n.s.
0.12
(0.28)
0.08
(0.19)
n.s.
0.11
(0.21)
0.08
(0.19)
n.s.
0.00
(0.00)
0.12
(0.22)
n.s.
ADAS score
(baseline)
11.3
(4.3)
10.1
(3.1)
n.s.
9.8
(4.2)
11.1
(4.0)
n.s.
9.3
(3.4)
10.6
(4.2)
n.s.
10.4
(3.1)
10.0
(3.9)
n.s.
ADAS score
(12 months follow-up)
10.6
(4.2)
8.5
(4.1)
n.s.
9.4
(4.0)
10.2
(4.8)
n.s.
10.5
(5.2)
10.6
(4.2)
n.s.
10.5
(4.3)
10.6
(5.0)
n.s.
ADAS score
(24 months follow-up)
10.9
(4.9)
9.6
(4.0)
n.s.
10.9
(4.8)
10.4
(4.7)
n.s.
10.5
(3.9)
10.4
(6.1)
n.s.
10.0
(4.9)
10.8
(6.2)
n.s.
ADAS score
(36 months follow-up)
9.9
(4.2)
9.3
(4.6)
n.s.
9.6
(4.0)
9.0
(4.3)
n.s.
10.3
(4.4)
8.7
(5.5)
n.s.
9.2
(4.2)
10.9
(6.0)
n.s.
p-values of t-tests after Bonferroni-Holm correction, n.s., not significant.
BMI, body mass index; DBP, diastolic blood pressure; GGT, γ -glutamyltransferase; ADAS, Alzheimer’s Disease Assessment Scale; CDR, Clinical Dementia Rating;
MMSE, Mini-Mental State Examination.
FEMALE SAMPLE
For women, the PLS regression model combining all measured
parameters was capable of explaining 32% of BrainAGE vari-
ance (R2 = 0.32, p < 0.01). As can be seen in Figure 5, GGT,
AST, ALT, and vitamin B12 contributed most to the variance in
BrainAGE. More specifically, higher BrainAGE scores were signif-
icantly related to increased levels of GGT (r = 0.25, p < 0.05),
increased AST (r = 0.20, p < 0.05) and ALT levels (r = 0.23, p <
0.05), and tended to be related to decreased levels of vitamin B12
(r = −0.17, p = 0.08). Thus, the pattern of relationships between
health and lifestyle markers and BrainAGE was different in the
female and male samples.
Quantifying the effects of these four most significant phys-
iological and clinical chemistry parameters on BrainAGE, the
BrainAGE scores of subjects with extremely low levels (i.e., 1st
quartile group) were tested against the BrainAGE scores of sub-
jects with extremely high levels (i.e., 4th quartile group) in each
of those four parameters (Figure 6). For GGT, AST, and ALT,
higher parameter values were related to higher BrainAGE scores,
thus suggesting accelerated brain aging. For vitamin B12, higher
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FIGURE 4 | Combined analysis of physiological and serum data
parameters in the male sample. BrainAGE score distributions of male
subjects with “healthy” markers (i.e., values equal to or below the medians
of BMI, DBP, GGT, and uric acid; n = 9) vs. “risky” markers (i.e., values
equal to or above the medians of BMI, DBP, GGT, and uric acid; n = 14;
p < 0.05). Gray boxes contain values between the 25th and 75th
percentiles of the groups, including the median. Error bars indicate data
within 1.5 times the interquartile range. The width of the boxes is
proportional to group size.
values were related to lower BrainAGE scores, thus suggesting a
protective effect on brain aging. For GGT, the absolute difference
of the mean BrainAGE scores was 6.1 years (p < 0.01); for AST, it
resulted in 3.1 years (p < 0.10); for ALT in 5.1 years (p < 0.05);
and for vitamin B12 in 4.8 years (p < 0.05). However, only GGT
survived the Bonferroni-Holm correction. Neither chronologi-
cal age, nor cognitive scores at baseline and follow-up differed
between 1st vs. 4th quartile groups (Table 6).
As already seen in the male sample, the effects on BrainAGE
scores were compounded when combining those four parameters.
More precisely, female subjects with values equal to or below
the medians of GGT, AST, ALT, as well as values equal to or
above the median of vitamin B12 (“healthy” clinical markers;
n = 14) vs. female subjects with values equal to or above the
medians of GGT, AST, ALT, as well as values equal to or below
the median of vitamin B12 (“risky” clinical markers; n = 13)
showed mean BrainAGE scores of −0.99 vs. 3.76 years, respec-
tively (p = 0.04; Figure 7). However, neither chronological age,
nor cognitive scores at baseline and follow-up differed between
both groups (Table 7).
Similar, but to a lesser extent as seen in the men’s data, these
results indicate a significant link between physiological and clini-
cal health markers and structural brain aging in women, whereas
no effects on cognitive scores could be found.
DISCUSSION
The scope of this study was the implementation of a novel MRI-
based biomarker derived from the recently presented BrainAGE
framework to quantify the effect of several common physiological
Table 5 | Means (SD) of BrainAGE scores, chronological age, and
cognitive scores in male subjects with “healthy” clinical markers
(i.e., values equal to or below the medians of BMI, DBP, GGT, and uric
acid) vs. “risky” clinical markers (i.e., values equal to or above the
medians of BMI, DBP, GGT, and uric acid).
Male Clinical markers p
“healthy” “risky”
BrainAGE score
(years)
−8.01
(7.11)
6.69
(6.48)
<0.05
Chronological age
(years)
75.6
(5.5)
73.0
(5.2)
n.s.
MMSE score
(baseline)
28.9
(0.9)
29.4
(0.7)
n.s.
MMSE score
(12 months follow-up)
29.7
(0.7)
29.8
(0.6)
n.s.
MMSE score
(24 months follow-up)
29.5
(0.8)
29.3
(0.9)
n.s.
MMSE score
(36 months follow-up)
29.4
(0.8)
28.6
(1.7)
n.s.
CDR score
(baseline)
0.00
(0.00)
0.00
(0.00)
n.s.
CDR score
(12 months follow-up)
0.06
(0.17)
0.04
(0.13)
n.s.
CDR score
(24 months follow-up)
0.12
(0.23)
0.00
(0.00)
n.s.
CDR score
(36 months follow-up)
0.00
(0.00)
0.04
(0.14)
n.s.
ADAS score
(baseline)
8.6
(4.7)
9.0
(2.9)
n.s.
ADAS score
(12 months follow-up)
9.8
(4.4)
7.9
(4.1)
n.s.
ADAS score
(24 months follow-up)
9.1
(4.0)
7.6
(3.3)
n.s.
ADAS score
(36 months follow-up)
8.6
(4.8)
8.8
(3.4)
n.s.
n.s., not significant.
ADAS, Alzheimer’s Disease Assessment Scale; CDR, Clinical Dementia Rating;
MMSE, Mini-Mental State Examination.
and clinical health markers on individual brain aging. Using
structural MRI data, the BrainAGE approach aggregates the
complex, multidimensional aging patterns across the whole brain
to one single value (i.e., the BrainAGE score) and subsequently
identifies pathological brain aging on an individual level. This
method has been shown to accurately and reliably estimating
the age of individual brains with minimal preprocessing and
parameter optimization using anatomical MRI scans (Franke
et al., 2010, 2012a). Additionally, higher BrainAGE scores were
recently demonstrated to be related to measures of clinical disease
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FIGURE 5 | PLS regression model of the female sample. When modeling
the relationships between BrainAGE and health parameters, the PLS
regression model explained 32% of variance in BrainAGE (p < 0.01). GGT,
AST, ALT, and vitamin B12 are the most significant physiological and clinical
chemistry parameters as they added most to the explained variance in
BrainAGE (top chart) and also showed the highest variable weights, i.e., the
highest impact in the regression model (bottom chart).
severity in AD patients, as well as prospective decline in cognitive
functioning (Franke et al., 2012a) and conversion to AD (Gaser
et al., 2013).
In this study, the BrainAGE approach was applied to a
new sample, which included 110 female and 118 male cog-
nitively unimpaired elderly subjects from the ADNI database.
The results provide evidence that a number of physiological
and clinical health parameters have significant effects on struc-
tural brain aging, hence possibly affecting the onset of dementia.
Furthermore, the effects of health measures on BrainAGE showed
gender-specific patterns.
In cognitively unimpaired elderly men the set of physiologi-
cal and clinical health markers under consideration could explain
39% of variance in BrainAGE. More specifically, several mark-
ers of poor health were significantly related to higher BrainAGE
scores, suggesting advanced brain atrophy. In particular, compo-
nents of the metabolic syndrome (including elevated values in
BMI, DBP, and uric acid) as well as markers of impaired liver
function (including elevated levels of GGT and uric acid) were
significantly related to increased BrainAGE scores of up to 9 years.
This is consistent with previous studies that associated lower
total brain volume as well as an increased risk of later dementia
with a higher BMI and visceral adipose tissue at mid-life (Chen
FIGURE 6 | The effects of extremely low vs. extremely high levels in
clinical markers on BrainAGE in the female sample. Mean BrainAGE
scores of female subjects in the 1st (plain) and the 4th quartiles (filled
squares) of the most significant physiological and clinical chemistry
parameters (i.e., GGT, AST, ALT, and vitamin B12). Error bars depict the
standard error of the mean (SEM). [(∗) p < 0.05 before Bonferroni-Holm
correction; ∗p < 0.05 after Bonferroni-Holm correction].
et al., 2009; Fitzpatrick et al., 2009; Debette et al., 2010) and
the metabolic syndrome (Enzinger et al., 2005). However, those
markers were neither related to cognitive scores at baseline, nor
up to three years later.
In cognitively unimpaired elderly women, 32% of variance in
BrainAGE was explained by the set of health and lifestyle markers
under consideration. In particular, markers of liver and kidney
functions (including ALT, AST, and GGT) as well as vitamin B12
levels were related to BrainAGE scores. Although it still remains
uncertain how vitamin B12 deficiency is linked to accelerated
brain atrophy, cognitive decline, and dementia (McMahon et al.,
2006; Aisen et al., 2008; Langan and Zawistoski, 2011), our results
support recent studies, which suggested a neuroprotective role for
vitamin B12 (Clarke et al., 1998, 2007; Czapski et al., 2012; Morris,
2012; Morris et al., 2012; Douaud et al., 2013; Hinterberger
and Fischer, 2013; Kim et al., 2013). This controversy in litera-
ture regarding the effects of vitamin B12 on brain structure and
function may be due to the heterogeneity of study samples con-
cerning age, gender, baseline cognition, and diagnosis etc. as well
as a heterogeneity of utilized analysis methods. Further, we did
not find any associations between BrainAGE and components
of the metabolic syndrome in the female sample. These results
are consistent with recent studies that also found gender-specific
relationships between (lifestyle-related) health markers and GM
atrophy (Taki et al., 2008) or even risk for AD (Chen et al., 2009).
Even more interesting, when combining the observed gender-
specific risk parameters, the effects on BrainAGE were profoundly
compounded in the male sample. This result is in line with
Luchsinger et al. (2005), reporting an increased risk of AD with
increased numbers of risk factors. However, in the female sample,
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Table 6 | Means (SD) of BrainAGE scores, chronological age and cognitive scores in the 1st and 4th quartile groups of the four most significant
physiological and clinical chemistry parameters within the female sample.
Female ALT AST GGT B12
1st
quartile
4th
quartile
p 1st
quartile
4th
quartile
p 1st
quartile
4th
quartile
p 1st
quartile
4th
quartile
p
BrainAGE score
(years)
−2.88
(6.04)
2.19
(6.19)
n.s.
−0.69
(7.29)
2.45
(7.44)
n.s.
−3.88
(6.78)
2.18
(7.04)
<0.05 1.87
(8.06)
−2.97
(6.83)
n.s.
Chronological age
(years)
76.8
(4.1)
76.0
(5.6)
n.s.
76.4
(4.2)
76.6
(5.9)
n.s.
77.5
(4.6)
74.5
(4.3)
n.s.
77.5
(5.0)
76.6
(4.0)
n.s.
MMSE score
(baseline)
29.1
(0.8)
29.1
(1.3)
n.s.
29.0
(1.1)
29.3
(0.7)
n.s.
29.3
(0.8)
29.4
(0.8)
n.s.
29.1
(1.1)
29.4
(0.7)
n.s.
MMSE score
(12 months follow-up)
28.9
(1.0)
29.2
(0.8)
n.s.
29.1
(0.9)
29.3
(0.8)
n.s.
29.3
(0.9)
29.5
(0.7)
n.s.
29.2
(1.0)
29.2
(1.2)
n.s.
MMSE score
(24 months follow-up)
29.2
(0.9)
29.0
(0.9)
n.s.
29.4
(0.9)
28.9
(1.1)
n.s.
29.1
(0.8)
29.3
(0.9)
n.s.
29.1
(1.1)
29.3
(0.9)
n.s.
MMSE score
(36 months follow-up)
29.5
(0.7)
28.9
(1.7)
n.s.
29.5
(0.9)
29.4
(0.9)
n.s.
29.3
(0.7)
29.3
(1.0)
n.s.
29.1
(1.5)
29.3
(0.8)
n.s.
CDR score
(baseline)
0.00
(0.00)
0.00
(0.00)
n.s.
0.00
(0.00)
0.00
(0.00)
n.s.
0.00
(0.00)
0.00
(0.00)
n.s.
0.00
(0.00)
0.00
(0.00)
n.s.
CDR score
(12 months follow-up)
0.00
(0.00)
0.07
(0.18)
n.s.
0.05
(0.15)
0.05
(0.15)
n.s.
0.00
(0.00)
0.05
(0.15)
n.s.
0.02
(0.10)
0.06
(0.17)
n.s.
CDR score
(24 months follow-up)
0.03
(0.12)
0.03
(0.12)
n.s.
0.03
(0.11)
0.07
(0.18)
n.s.
0.00
(0.00)
0.07
(0.17)
n.s.
0.02
(0.10)
0.03
(0.11)
n.s.
CDR score
(36 months follow-up)
0.11
(0.21)
0.00
(0.00)
n.s.
0.14
(0.23)
0.09
(0.27)
n.s.
0.08
(0.19)
0.09
(0.25)
n.s.
0.07
(0.18)
0.06
(0.16)
n.s.
ADAS score
(baseline)
8.9
(3.7)
8.4
(3.3)
n.s.
9.8
(4.8)
9.0
(3.8)
n.s.
8.9
(4.3)
8.0
(4.6)
n.s.
9.1
(5.2)
9.3
(4.6)
n.s.
ADAS score
(12 months follow-up)
7.2
(3.9)
7.2
(3.4)
n.s.
6.8
(3.3)
8.1
(3.8)
n.s.
7.2
(4.7)
7.0
(3.4)
n.s.
7.7
(3.8)
7.4
(4.3)
n.s.
ADAS score
(24 months follow-up)
8.6
(5.1)
9.5
(5.6)
n.s.
8.4
(4.4)
10.5
(5.2)
n.s.
9.4
(5.1)
7.3
(4.9)
n.s.
8.1
(4.1)
8.8
(3.7)
n.s.
ADAS score
(36 months follow-up)
7.5
(3.6)
7.9
(3.5)
n.s.
6.1
(3.2)
9.6
(5.1)
n.s.
7.2
(2.8)
7.6
(4.3)
n.s.
7.5
(3.6)
8.0
(3.5)
n.s.
p-values of t-tests after Bonferroni-Holm correction; n.s., not significant.
ALT, alanin-aminotransferase; AST, aspartat-aminotransferase; GGT, γ -glutamyltransferase; ADAS, Alzheimer’s Disease Assessment Scale; CDR, Clinical Dementia
Rating; MMSE, Mini-Mental State Examination.
the compounding effect was much smaller, but still statistically
significant. Additionally, the set of serum markers under con-
sideration could explain 39% of variance in BrainAGE in men,
opposed to 32% in women. When analyzing men and women
together, only components of the PLS pattern of the male sample
were significantly related to increased BrainAGE scores (data not
shown). Thus, the present study strongly suggests distinct gender-
specific patterns of brain aging associated with certain health
parameters, supporting the idea of the newly founded area of gen-
der medicine (Pinn, 2003) that the phenomenon of aging as well
as the prevention, detection, treatment, and outcome of illnesses
affect men and women differently, including differences in basic
aspects of their normal function and their experience of the same
illness. Especially for AD, it was suggested that the underlying
mechanisms may be different in men and women (Grossi et al.,
2005). Therefore, in the design of future studies, it should be
imperative that there be enough women and men for appropriate
gender-specific analyses (Azad et al., 2007).
Because this study was cross-sectional, it remains unclear
whether certain health and lifestyle factors are cause or conse-
quence of the associations found. Nevertheless, it strongly sup-
ports previously published results of personal lifestyle and overall
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FIGURE 7 | Combined analysis of physiological and serum data
parameters in the female sample. BrainAGE score distributions of female
subjects with “healthy” clinical markers (i.e., values equal to or below the
medians of GGT, ALT, AST, and values equal to or above the median of
vitamin B12; n = 14) vs. “risky” clinical markers (i.e., values equal to or
above the medians of GGT, ALT, AST, and values equal to or below the
median of vitamin B12; n = 13; p < 0.05). Gray boxes contain values
between the 25th and 75th percentiles of the groups, including the median.
Error bars indicate data within 1.5 times the interquartile range. The width
of the boxes is proportional to group size.
health being related to brain health, and extends this evidence
by providing a small subset of serum markers that could explain
nearly 40 percent of changes in BrainAGE.
Even more important, this study is the first that quantified
the effects of several health markers on individual brain aging
in terms of years. Relying on the assumption of AD being pre-
ceded by an acceleration in brain atrophy that resembles advanced
aging (e.g., Driscoll et al., 2009; Cao et al., 2010; Spulber et al.,
2010; Dukart et al., 2011; Jones et al., 2011; Saetre et al., 2011),
subjects with increased BrainAGE scores are supposed to have
a greater risk for conversion to AD. However, the acceleration
of spatiotemporal brain atrophy might only be seen in subjects
in a preclinical stage, while in AD patients additional disease-
specific pathological changes are occurring. As recently shown
by Dukart et al. (2013a,b), the magnitude of GM atrophy in
healthy aging was comparable to the GM atrophy associated with
increasing AD symptom severity within the age range of 50–80
years. Additionally, AD symptom severity was associated with
age- and symptom severity-related add-ons in GM atrophy to
normal age-related atrophy. Thus, and as already shown in MCI
and AD subjects (Franke et al., 2012a; Gaser et al., 2013), appar-
ently cognitively unimpaired subjects showing accelerated brain
aging may have a greater risk for prospective worsening of cogni-
tive functions and conversion to AD. However, cognitive reserve,
genetic status, education level, socioeconomic status or lifestyle
may protect subjects from pathological brain aging or acceler-
ated cognitive decline despite high BrainAGE scores (Snowdon,
2003; Fotenos et al., 2008; Chen et al., 2009; Querbes et al., 2009;
Table 7 | Means (SD) of BrainAGE scores, chronological age, and
cognitive scores in female subjects with “healthy” clinical markers
(i.e., values equal to or below the medians of GGT, ALT, AST, and
values equal to or above the median of vitamin B12) vs. “risky”
clinical markers (i.e., values equal to or above the medians of GGT,
ALT, AST, and values equal to or below the median of vitamin B12).
Female Clinical markers p
“healthy” “risky”
BrainAGE score
(years)
−0.99
(4.54)
3.76
(6.89)
<0.05
Chronological age
(years)
76.9
(4.0)
76.6
(4.7)
n.s.
MMSE score
(baseline)
29.2
(1.0)
29.4
(0.6)
n.s.
MMSE score
(12 months follow-up)
29.1
(1.2)
29.3
(0.8)
n.s.
MMSE score
(24 months follow-up)
29.2
(1.0)
28.7
(1.0)
n.s.
MMSE score
(36 months follow-up)
29.5
(0.7)
28.8
(1.8)
n.s.
CDR score
(baseline)
0.00
(0.00)
0.00
(0.00)
n.s.
CDR score
(12 months follow-up)
0.04
(0.14)
0.05
(0.15)
n.s.
CDR score
(24 months follow-up)
0.00
(0.00)
0.09
(0.20)
n.s.
CDR score
(36 months follow-up)
0.06
(0.17)
0.15
(0.34)
n.s.
ADAS score
(baseline)
7.4
(4.9)
6.6
(3.8)
n.s.
ADAS score
(12 months follow-up)
7.0
(4.0)
5.6
(3.4)
n.s.
ADAS score
(24 months follow-up)
8.1
(4.1)
7.1
(4.5)
n.s.
ADAS score
(36 months follow-up)
6.6
(4.2)
6.9
(5.0)
n.s.
n.s., not significant.
ADAS, Alzheimer’s Disease Assessment Scale; CDR, Clinical Dementia Rating;
MMSE, Mini-Mental State Examination.
Mangialasche et al., 2013). Future work will disentangle age- and
disease-specific influences on the estimation of BrainAGE score to
subsequently account for those influences.
Furthermore and similarly to other studies using the ADNI
data and adopting its diagnostic criteria, a proportion of our sam-
ple of apparently cognitively unimpaired subjects might have a
preclinical AD pathology. In our samples, seven female and 8
male subjects showed baseline MMSE scores lower than 28, thus
might have a preclinical AD pathology. However, excluding those
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subjects from the analyses did not change the results substan-
tially (data not shown), i.e., the patterns of gender-specific risk
parameters and its relations to BrainAGE remained the same.
Further research is therefore needed to extend our results and
explore the longitudinal relationships between individual brain
aging and miscellaneous factors (e.g., lifestyle, cognitive reserve,
genetic status) in a larger population-based sample. Furthermore,
the relationship between the duration of exposure to risk factors
and accelerated brain aging, and whether reversal of modifiable
factors might decelerate the progression of brain aging, should be
explored.
Although applying the BrainAGE method results in single
global estimation scores of the individual “brain age”, it accounts
for the multidimensional aging pattern across all voxels in the
brain.With correlations between chronological age and estimated
brain age of r = 0.92 in healthy adults, aged 20–86 years (Franke
et al., 2010), and r = 0.93 in healthy children and adolescents,
aged 5–18 years (Franke et al., 2012b), the BrainAGE frame-
work has proven to be a straightforward method to accurately
and reliably estimate brain age with minimal preprocessing and
parameter optimization. Most remarkably, although brain mat-
uration in childhood as well as brain aging in late life comprise
very complex, multidimensional, and highly variable processes
(Good et al., 2001; Wilke et al., 2003; Lenroot and Giedd, 2006;
Lebel and Beaulieu, 2011), the confidence intervals of estimated
brain age did not change as a function of age (Franke et al., 2010,
2012b), underlining the potential of the approach to correctly
capture the multidimensional characteristics of the different mat-
urational and aging processes occurring in childhood and old age,
respectively. Additionally, the BrainAGEmethod proved its ability
to provide very stable and reliable estimates of brain aging—
even across different scanners (Franke et al., 2012a). However,
the BrainAGE framework only provides information on the mag-
nitude of the deviation in “brain aging” from the normal aging
process, but not which regions are affected and to what extent.
Future work will focus on local quantitative assessment of all
regional alterations in a single patient’s brain to reveal informa-
tion about the areas that cause the difference between estimated
“brain age” and chronological age.
In summary, accelerated brain aging in cognitively unimpaired
elderly subjects is related to several physiological and clinical
markers of poor health, whereas a protective effect on brain aging
is observed for markers of good health. Since accelerated brain
atrophy was shown to precede cognitive impairment in MCI and
AD (Frisoni et al., 2010; Jack et al., 2010), this study suggests
that a good health, including a normal weight, appropriate liver
and kidney functions, and sufficient supply of vitamin B12 (Steele
et al., 2007; Solfrizzi et al., 2008), can prevent or at least slow
down acceleration in brain aging and certain disease processes.
However, gender-specific mechanisms should be taken care of in
future studies.
As BrainAGE scores are calculated from a single T1-weighted
MRI per subject, using processing techniques that can be fully
automated with multi-center data, this approach may be eas-
ily implemented into clinical practice in order to encourage
the identification of subtle, yet clinically-significant, changes in
brain structure. With regards to health and lifestyle markers, the
implications of this study may lead to a clinical tool that iden-
tifies people at risk of faster degradation of brain structure and
function and potential risk for dementias, thus contributing to an
early diagnosis of neurodegenerative diseases and facilitating early
treatment or preventative interventions.
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